Granules India's Gagillapur facility completes INFARMED inspection

06 Jan 2017 Evaluate

Granules India has received the inspection report from INFARMED (InstitutoNacional da Farmacia E Do Medicamento), Portugal with 11 observations. The Gagillapur facility manufactures Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). INFARMED Portugal had conducted a renewal inspection on the company’s facility located at Gagillapur, Telangana, India.

The company has initiated necessary steps to address the observations of the inspection agency and will submit its response with a corrective and preventive action plan within stipulated time. The company will also be requesting the INFARMED for re-inspection of the Gagillapur facility at the earliest.

Granules India is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs).

Granules India Share Price

560.65 -5.90 (-1.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×